997 related articles for article (PubMed ID: 27045225)
1. Vascular endothelial growth factor and diabetic macular edema.
Lally DR; Shah CP; Heier JS
Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
3. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.
Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T
Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425
[TBL] [Abstract][Full Text] [Related]
4. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
5. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.
; ; Aiello LP; Beck RW; Bressler NM; Browning DJ; Chalam KV; Davis M; Ferris FL; Glassman AR; Maturi RK; Stockdale CR; Topping TM
Ophthalmology; 2011 Dec; 118(12):e5-14. PubMed ID: 22136692
[TBL] [Abstract][Full Text] [Related]
6. The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection.
Takamura Y; Tomomatsu T; Matsumura T; Arimura S; Gozawa M; Takihara Y; Inatani M
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):4741-6. PubMed ID: 25028357
[TBL] [Abstract][Full Text] [Related]
7. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.
Mukkamala L; Bhagat N; Zarbin MA
Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
9. Diabetic macular edema: Evidence-based management.
Browning DJ; Stewart MW; Lee C
Indian J Ophthalmol; 2018 Dec; 66(12):1736-1750. PubMed ID: 30451174
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
Cai S; Bressler NM
Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
[TBL] [Abstract][Full Text] [Related]
11. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
[TBL] [Abstract][Full Text] [Related]
13. TREATMENT PATTERNS AND 2-YEAR VISION OUTCOMES WITH BEVACIZUMAB IN DIABETIC MACULAR EDEMA: An Analysis From a Large U.S. Integrated Health Care System.
Fong DS; Luong TQ; Contreras R; Jimenez JJ; Custis PH; Patel V; Campbell JH
Retina; 2018 Sep; 38(9):1830-1838. PubMed ID: 28796143
[TBL] [Abstract][Full Text] [Related]
14. Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study.
Karst SG; Deak GG; Gerendas BS; Waldstein SM; Lammer J; Simader C; Guerin T; Schmidt-Erfurth UM
JAMA Ophthalmol; 2018 Apr; 136(4):315-321. PubMed ID: 29494727
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
[TBL] [Abstract][Full Text] [Related]
17. Diabetic Macular Edema: Traditional and Novel Treatment.
Tomić M; Vrabec R; Poljičanin T; Ljubić S; Duvnjak L
Acta Clin Croat; 2017 Mar; 56(1):124-132. PubMed ID: 29120156
[TBL] [Abstract][Full Text] [Related]
18. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
19. Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12-month prospective clinical trial.
Blindbaek SL; Peto T; Grauslund J
Acta Ophthalmol; 2020 Jun; 98(4):353-359. PubMed ID: 31654501
[TBL] [Abstract][Full Text] [Related]
20. Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.
Dupas B; Castro-Farias D; Girmens JF; Eginay A; Couturier A; Villeroy F; Delyfer MN; Creuzot-Garcher C; Giocanti-Auregan A; Béral L; Arndt C; Mesnard C; Vicaut E; Chaumet-Riffaud P; Durand-Zaleski I; Paques M
Trials; 2024 Apr; 25(1):273. PubMed ID: 38649937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
